TransCode Therapeutics RNAZ announced that it is floating a secondary issue of around 5.94 million shares of its common stock to the public at an issue price of $1.22 per share, amounting to $7.5 ...

TransCode Therapeutics recently received approval for a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers. In this clinical trial, up to 12 patients will be given a ...

TransCode Therapeutics Inc (NASDAQ: RNAZ) shares are trading higher Thursday after the company announced it received written authorization from the FDA to proceed with its ...

TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.

Shares of TransCode Therapeutics stock opened at $0.46 on Friday. TransCode Therapeutics has a 12 month low of $0.38 and a 12 month high of $66.33. The business’s 50-day moving average price is ...

Google has decided that YouTube demands such a huge transcoding workload that it needs to build its own server chips. The company detailed its new "Argos" chips in a YouTube blog post, a CNET ...